Alumis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- $685.4M
- Website
- http://www.alumis.com
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06962774
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Floridian Clinical Research, Miami Lakes, Florida, United States
🇺🇸Advanced Pharma CR, Miami, Florida, United States
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06952634
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque PsoriasisPsoriasis (PsO)PsoriasisModerate PsoriasisSevere Psoriasis
- Interventions
- Drug: Open-Label ESK-001Drug: Blinded ESK-001Drug: Placebo
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 1680
- Registration Number
- NCT06846541
- Locations
- 🇨🇦
Derm Effects, London, Ontario, Canada
🇨🇦Lynderm Research, Markham, Ontario, Canada
🇨🇦North Bay Dermatolgy Centre, North Bay, Ontario, Canada
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06588738
- Locations
- 🇭🇺
Orvostudomanyi Kutato es Fejleszto Kft, Debrecen, Hungary
🇭🇺Allergo Derm Bakos Kft, Szolnok, Hungary
🇭🇺Medmare Bt, Veszprém, Hungary
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06586112
- Locations
- 🇺🇸
Alliance Dermatology, Phoenix, Arizona, United States
🇺🇸Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Northwest Arkansas Clinical Trials Center (NWACTC), PLLC, Rogers, Arkansas, United States
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 388
- Registration Number
- NCT05966480
- Locations
- 🇧🇬
Investigator Site #5521, Plovdiv, Bulgaria
🇧🇬Investigator Site #5529, Ruse, Bulgaria
🇧🇬Investigator Site #5522, Sofia, Bulgaria
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
- Conditions
- Noninfectious PanuveitisUveitis Posterior Non-InfectiousUveitis, Intermediate
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05953688
- Locations
- 🇺🇸
Investigator Site #1076, Palisades Park, New Jersey, United States
🇺🇸Investigator Site #1064, Erie, Pennsylvania, United States
🇺🇸Investigator Site #1073, Los Angeles, California, United States
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 165
- Registration Number
- NCT05739435
- Locations
- 🇺🇸
Investigator Site #1018, Los Angeles, California, United States
🇺🇸Investigator Site #1035, Macon, Georgia, United States
🇺🇸Investigator Site #1017, Owensboro, Kentucky, United States
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 228
- Registration Number
- NCT05600036
- Locations
- 🇺🇸
Investigator Site #1035, Macon, Georgia, United States
🇺🇸Investigator Site #1017, Owensboro, Kentucky, United States
🇺🇸Investigator Site #1031, New Brighton, Minnesota, United States
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
- Conditions
- Safety and Tolerability
- Interventions
- Other: Placebo
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 49
- Registration Number
- NCT05431634
- Locations
- 🇺🇸
Alumis Central site, Glendale, California, United States